Tumors Expressing the Cytosine Deaminase Suicide Gene Can Be Eliminated in Vivo with 5-Fluorocytosine and Induce Protective Immunity to Wild Type Tumor

Cancer Research

Volumn 54, Issue 6, 1994, Pages 1503-1506

  Mullen, Craig A ^a   Coale, Melissa M ^a   Lowe, Robert ^a   Blaese, R Michael ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL;

ADENOCARCINOMA; ANIMAL CELL; ARTICLE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; FIBROSARCOMA; GENE EXPRESSION; GENE THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL DESTRUCTION;

ANIMAL; BACTERIAL PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; FLUCYTOSINE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; IMMUNITY, NATURAL; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NUCLEOSIDE DEAMINASES; RETROVIRIDAE; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0028297316     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Danielsen, S., Kilstrup, M., Barilla, K., Jochimsen, B., and Neuhard, J. Characterization of the Escherichia coli codBA Operon encoding cytosine permease and cytosine deaminase. Mol. Microbiol., 6: 1335-1344, 1992.
2. Kilstrup, M., Meng, L.M., Neuhard, J., and Nygaard, P. Genetic evidence for a repressor of synthesis of cytosine deaminase and purine biosynthesis enzymes in Escherichia coli. J. Bacteriol., 171: 2124-2127, 1989.
3. Andersen, L., Kilstrup, M., and Neuhard, J. Pyrimidine, purine and nitrogen control of cytosine deaminase synthesis in Escherichia coli K12. Involvement of the glnLG and purR genes in the regulation of codA expression. Arch. Microbiol., 152: 115-118, 1989.
4. Polak, A., and Scholer, H.J. Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy (Basel), 21: 113-130, 1975.
5. Polak, A., Eschenhof, E., Fernex, M., and Scholer, H.J. Metabolic studies with 5-fluorocytosine-14-C in mouse, rat, rabbit, dog and man. Pharmacology (Basel), 22: 137-153, 1976.
6. Mullen, C.A., Kilstrup, M., and Blaese, R.M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA, 89: 33-37, 1992.
7. Austin, E.A., and Huber, B.E. A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol. Pharmacol., 43: 380-387, 1993.
8. Restifo, N.P., Esquivel, F., Asher, A.L., Stotter, H., Barth, R.J., Bennick, J.R., Mule, J.J., Yewdell, J.W., and Rosenberg, S.A. Defective presentation of endogenous antigens by a murine sarcoma: implications for the failure of an anti-tumor immune response. J. Immunol., 147: 1453-1459, 1991.
9. Miller, A.D., and Buttimore, C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol., 6: 2895-2902, 1986.
10. Cornetta, K., and Anderson, W.F. Protamine sulfate as an effective alternative to polybrene in retroviral-mediated gene-transfer: implications for human gene therapy. J. Virol. Methods, 23: 187-194, 1989.
11. Altman, D.G. Practical Statistics for Medical Research. London: Chapman and Hall, 1991.
12. Mansour, S.L., Thomas, K.R., and Capecchi, M.R. Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature (Lond.), 336: 348-352, 1988.
13. Riddell, S.R., Greenberg, P.D., Overell, R.W., Loughran, T.P., Gilbert, M.J., Lupton, S.D., Agosti, J., Scheeler, S., Coombs, R.W., and Corey, L. Phase 1 study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T-cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. Hum. Gene Ther., 3: 319-338, 1992.
14. Moolten, F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 46: 5276-5281, 1986.
15. Culver, K.W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E.H., and Blaese, R.M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (Washington DC), 256: 1550-1552, 1992.
16. Oldfield, E.H., Ram, Z., Culver, K.W., Blaese, R.M., DeVroom, H.L., and Anderson, W.F. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther., 4: 39-69, 1993.
17. Senter, P.D., Su, P.C., Katsuragi, T., Sakai, T., Cosand, W.L., Hellström, I., and Hellström, K.E. Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates. Bioconjug. Chem., 2: 447-451, 1991.
18. Miller, A.D., and Rosman, G.J. Improved retroviral vectors for gene transfer and expression. Biotechniques, 7: 980-990, 1989.
19. Palmer, T.D., Rosman, G.J., Osborne, W.R.A., and Miller, A.D. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc. Natl. Acad. Sci. USA, 88: 1330-1334, 1991.
20. Huber, B.E., Austin, E.A., Good, S.S., Knick, V.C., Tibbels, S., and Richards, C.A. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res., 53: 4619-4626, 1993.